Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer (NCT06840483)
Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).
Who can join: Review the eligibility criteria below.
Location: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC) — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC) — Baltimore, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Siteman Cancer Center — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- Compass Oncology - Rose Quarter Cancer Center — Portland, Oregon
- Texas Oncology San Antonio — San Antonio, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- UZ Leuven — Leuven,
- Oncopole Claudius Regaud — Toulouse,
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST — Meldola, Forli/Cesena
- Clinica Oncologica-Azienda Ospedaliero Universitaria delle Marche — Ancona,
- Istituto Europeo di Oncologia — Milan,
- Hospital Quironsalud Barcelona — Barcelona,
- Hospital Beata Maria Ana — Madrid,
- Hospital Universitario 12 de Octubre — Madrid,
- The Royal Marsden NHS Foundation Trust — London,
📞 Contact the Study Coordinator
Phone: (855) 694-6725
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.